Impact of Percutaneous Transvenous Mitral Commissurotomy on The Left Atrial Appendage Function in Patients With Mitral Stenosis.
NCT ID: NCT06340997
Last Updated: 2024-04-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
25 participants
INTERVENTIONAL
2024-07-01
2027-08-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Late Clinical Outcomes of Percutaneous Mitral Commissurotomy in Patients With Mitral Stenosis
NCT04112108
Coronary Physiology Peri-Transcatheter Left-sided Valvular Interventions
NCT05374733
Left Chamber Function in Mitral Regurgitation and Predicting Outcome After Replacement and Targeting for Early Surgery
NCT03870516
Treatment of Concomitant Mitral Regurgitation by Mitral Valve Clipping in Patients With Successful Transcatheter Aortic Valve Implantation.
NCT04009434
Mitral Valve Area Using 3-dimensional Transesophageal Echocardiography
NCT01694251
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Chronic pressure and volume overload imposed by MS causes left atrial (LA) and Left Atrial Appendage (LAA) dysfunction leading to reduced blood flow velocities thereby producing stasis of blood, reduced LA and LAA ejection fraction and atrial fibrillation (AF).
* These factors predispose to formation of LA and LAA thrombi in MS and result in thromboembolic episodes. Risk of cerebrovascular accident (CVA) is increased approximately five-fold in non-rheumatic AF and 17-fold in patients with MS with AF. Even patients of MS in sinus rhythm with depressed LA and LAA function are at increased risk of CVA. Assessment of LAA function is helpful in predicting the risk of thromboembolism .
* PTMC can improve the function of the LAA by reducing the left atrial pressure and increasing the blood flow through the mitral valve.
* Echocardiography, particularly transesophageal echocardiography (TEE), is currently the modality of choice for evaluation of the LAA. Transesophageal echocardiography (TEE) allows semi-invasive, highly accurate imaging of the functional efficiency of LAA by LAA Doppler and Doppler tissue imaging (DTI) .
* MS causes decreased LAA Doppler and DTI velocities in patients even with sinus rhythm . So, this study aims to evaluate effect of successful PTMC on LAA function by TEE Doppler and DTI (doppler tissue imaging).
* Fractional area change (FAC): The FAC is a measure of the percentage of change in the area of the LAA during systole. A higher FAC indicates a more contractile LAA.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with mitral stenosis
Transesophageal echocardiography
* D.Echocardiography(Transthoracic and transesophageal):
* 2D echocardiography (to detect LA function, severity of MS and Wilkins score).
The following conventional parameters were measured :
* left atrial volume index (LAVi), and left ventricular ejection fraction (LVEF) by modified biplane Simpson's rule , left atrial emptying fraction calculated as (LAVi max-LAVi min)/LAVi max × 100 ,\]degree of concomitant mitral regurgitation. The maximum and minimum LAA areas were measured by planimetry. LAA area change (%) was calculated using the following formula: LAA area change = \[(maximal LAA area-minimal LAA area)/maximal LAA area\] × 100.
* Transesophageal echocardiogram (TEE) (to detect LAA function) .
* LAA flow velocity patterns by pulsed-wave Doppler
* Early diastolic emptying velocity
* Late diastolic emptying velocity or LAA contraction flow
* LAA filling velocity
* Systolic reflection waves
* Two-Dimensional- LAA fractional area change (LAAAC%)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Transesophageal echocardiography
* D.Echocardiography(Transthoracic and transesophageal):
* 2D echocardiography (to detect LA function, severity of MS and Wilkins score).
The following conventional parameters were measured :
* left atrial volume index (LAVi), and left ventricular ejection fraction (LVEF) by modified biplane Simpson's rule , left atrial emptying fraction calculated as (LAVi max-LAVi min)/LAVi max × 100 ,\]degree of concomitant mitral regurgitation. The maximum and minimum LAA areas were measured by planimetry. LAA area change (%) was calculated using the following formula: LAA area change = \[(maximal LAA area-minimal LAA area)/maximal LAA area\] × 100.
* Transesophageal echocardiogram (TEE) (to detect LAA function) .
* LAA flow velocity patterns by pulsed-wave Doppler
* Early diastolic emptying velocity
* Late diastolic emptying velocity or LAA contraction flow
* LAA filling velocity
* Systolic reflection waves
* Two-Dimensional- LAA fractional area change (LAAAC%)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Patient not eligible to PTMC.
* Patient with severe heart failure (NHYA class IV) .
* Patient with previous Cerebrovascular accident .
* Patient with contraindication to TEE ( esophageal disease like stricture , diverticuli, varices, …, uncooperative patient )
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assiut University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mohamed Ahmed Ali Ismail
Resident
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Mitral Stenosis
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.